STEVEN GALETTA, MD: Well, I think it's very encouraging that we have a lot of information that is summating, that we have interferon compounds that appear to be consistently working both to delay the clinical onset of MS, to delay the next clinical event, and to have a positive MRI scan. Couple that with the Copaxone data, which over the eight year period of time, also seems to alter the course of MS when looking at a natural history cohort, is very encouraging to physicians that over the long term they're doing the right thing by having these patients on immunomodulatory therapy.

All evidence is pointing that the earlier therapy is initiated, the better the patients seem to be doing down the line seven, eight years going forward.